Skip to main content

Table 1 Clinical attributes of the HAM/TSP patients enrolled in this study (n = 383)

From: Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net)

Time-Points (Years)

Median

(IQR)

 Age at Onset

45

(32 – 56)

 Age at Diagnosis

53

(42 – 62)

 Age (at Presenta)

63

(56 – 69)

 Diagnosis Delay (Time from Onset to Diagnosis)

5

(1 – 12)

 Disease Duration (Time from Onset to Presenta)

17

(8 – 26)

Scales/Surveys (Scores)

Median

(IQR)

 OMDS (Range: 0 – 13)

5.0

(5.0 – 7.0)

 IPEC-1 Gait Subsection (Range: 0 – 11)

4.0

(3.0 – 8.0)

 ICIQ-SF (Range: 0 – 21)

6.0

(0.0 – 11.0)

 I-PSS (Range: 0 – 30)

14.5

(6.0 – 22.0)

 OABSS (Range: 0 – 15)

6.0

(2.3 – 10.0)

 N-QOL (Range: 0 – 100)

91.7

(74.5 – 100.0)

 HAQ-DI (Range: 0 – 3)

1.1

(0.8 – 1.6)

 SF-36 Physical Functioning (National Average ± SD: 50 ± 10)b

-3.5

(-10.7 – 14.5)

 SF-36 General Health (National Average ± SD: 50 ± 10)b

38.9

(32.5 – 45.8)

Inquiries

Responses

Subjects

(Percentage)

 Sex:

Female

284

(74.2 %)

 

Male

99

(25.8 %)

 Initial Symptoms (inclusive):

Gait Disturbance

313

(81.9 %)

 

Urinary Disturbance

147

(38.5 %)

 

Sensory Disturbance (in legs)

53

(13.9 %)

 

Other

115

(30.0 %)

 History of Blood Transfusion:

Yes (Total)

73

(19.1 %)

 

Yes, Pre-1986

57

(14.9 %)

 

Unknown

3

(0.8 %)

 Urinary Dysfunction:

No Symptoms

29

(7.6 %)

 

Symptoms or Using Medication

234

(61.3 %)

 

Using Catheters

108

(28.3 %)

 

Other Management Strategy

11

(2.9 %)

 Bowel Dysfunction:

No Symptoms

87

(22.8 %)

 

Symptoms or Using Medication

256

(67.0 %)

 

Using Enemas

33

(8.6 %)

 

Other Management Strategy

6

(1.6 %)

 Leg Numbness:

None

125

(32.7 %)

 

Occasional

73

(19.1 %)

 

Severe

184

(48.2 %)

 Leg Pain:

None

215

(56.3 %)

 

Occasional

78

(20.4 %)

 

Severe

89

(23.3 %)

  1. Data are summarized using the median and interquartile range (IQR) or the number of subjects and the percentage of total subjects (%). The full names of the scales and surveys shown are as follows: Osame Motor Disability Score (OMDS), Health Assessment Questionnaire – Disability Index (HAQ-DI), Insituto de Pesquisa Clinica Evandro Chagas Disability Score (IPEC)-1, International Consultation on Incontinence Questionnaire – Short Form (ICIQ-SF), International Prostate Symptom Score (I-PSS), Overactive Bladder Symptom Score (OABSS), Nocturia Quality of Life (N-QOL), and MOS 36-Item Short-Form Health Survey (SF-36). Higher scores on N-QOL and SF-36 indicate better health, whereas the opposite is true for all other scales and surveys. n values vary between n = 363 and n = 383 due to incomplete data
  2. aPresent is defined as the time of the subject’s initial HAM-net interview
  3. bThe median values for the remaining six SF-36 sub-scores were all within one standard deviation of the national average (40 – 60) and are not shown in this table